Skip to content
DataLookout
Menu

NCT06321536

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified Show 7 more changesShow less
    • Eligibility criteria expanded, about 30 words
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 60 to confirmed 58
    • Primary completion date changed from estimate of Jul 2026 to Jul 8, 2026
    • Study completion date: Dec 2026 to Jan 2027
    • Secondary endpoints revised (3)
    • Site details revised at 4 of 4 sites
  2. Notable Enrollment target: 200 to 60
    • Primary completion date: Dec 2025 to Jul 2026
    • Study sites: 1 to 4
    • Study completion date: Dec 2025 to Dec 2026
    v5
  3. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Eligibility criteria shortened, about 4 words
    • Start date changed from estimate of Jan 2025 to Jan 13, 2025
    • Study description shortened, about 46 words
    • Site details revised
  4. Notable Start date: Oct 2024 to Jan 2025
    • Primary and study completion dates: Jun 2025 to Dec 2025
    v3
  5. Notable Start date: May 2024 to Oct 2024v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Difference in number of solicited Adverse Events (AEs)
Timeframe: Day 0, Day 7 post-intervention
Difference in severity of solicited AEs
Timeframe: Day 0, Day 7 post-intervention
Difference in number of unsolicited AEs
Timeframe: Day 0, Day 28 post-intervention
Difference in severity of unsolicited AEs
Timeframe: Day 0 and Day 28
Number of participants by composite MDRO Colonization and survival status
Timeframe: Day 28 post-intervention

Secondary (3)

Count of serious AEs (SAEs)
Count of AEs of Special Interest (AESIs)
Number of participants by category-specific MDRO Colonization and survival status

Arms and interventions

Group 1: microbiota therapy (MT)Experimental

Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition).

Group 2: ObservationNo intervention

Group 2 will be assigned to observation.

Drugs: Allogeneic Microbiota in Glycerol (9%) (AMG)

Sites

4 sites in 1 country